Therapeutic Delivery – Products

Aiming to improve exosome purification process that is currently slowing adoption of promising gene therapies and other new modalities.

Study met primary endpoint and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE® in 30 seconds using Halozyme’s proprietary high-volume auto-injector.

Linkam Scientific Instruments showcased its range of temperature and environmental control microscopy stages – the DSC450, THMS600, and MFS – at this year’s Advanced Materials Show (AMS) in Columbus, Ohio.

Partnership between two Canadian life sciences leaders offers a commercial GMP manufacturing solution for Acuitas’ licensed partners developing promising next generation therapies.

SPARTA technology to accelerate the development, manufacture and quality control of nanoparticles used for gene therapies, vaccines, and cancer drugs.

TherageniX, have been awarded a £995,000 grant from Innovate UK. The funding will support the development of the Company’s gene therapy in a powder, a non-viral gene delivery system to improve tissue regeneration following surgery.

The National Institutes of Health selected Exothera S.A. therapeutics to develop the manufacturing process for NIH’s intranasal vaccine against SARS-CoV-2.

MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), announced the signing of a strategic partnership with Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies.

This content pack contains a variety of webinar and technical note resources to support you in building better genetic medicine products. Download this content pack to discover optimized methods for impurity and integrity analysis.

This content pack contains a variety of webinars, technical notes and a compendium of resources to help you overcome a variety of common lentiviral development challenges. Download this content pack to discover innovative solutions for more comprehensive proteome characterization.